human | Q5 |
P6634 | LinkedIn personal profile ID | katrinaalbert12 |
P2798 | Loop ID | 670421 |
P496 | ORCID iD | 0000-0002-6129-4992 |
P2002 | X username | katecholamine |
P734 | family name | Albert | Q10729205 |
Albert | Q10729205 | ||
Albert | Q10729205 | ||
P735 | given name | Katrina | Q16277723 |
Katrina | Q16277723 | ||
P106 | occupation | researcher | Q1650915 |
Q39139260 | AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models. |
Q93061235 | Cerebral Dopamine Neurotrophic Factor Diffuses Around the Brainstem and Does Not Undergo Anterograde Transport After Injection to the Substantia Nigra |
Q50736097 | Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat. |
Q90478132 | Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease |
Q64090835 | Neuroprotective and reparative effects of endoplasmic reticulum luminal proteins - mesencephalic astrocyte-derived neurotrophic factor and cerebral dopamine neurotrophic factor |
Q38821744 | Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse |
Q54941237 | Post-stroke Intranasal (+)-Naloxone Delivery Reduces Microglial Activation and Improves Behavioral Recovery from Ischemic Injury. |
Search more.